Traffic Lights Intervention Reduces Therapeutic Inertia: A Randomized Controlled Trial in Multiple Sclerosis Care

Gustavo Saposnik, Muhammad Mamdani, Xavier Montalban, Maria Terzaghi, Berenice Silva, Maria Laura Saladino, Philippe N Tobler, Fernando Caceres, Gustavo Saposnik, Muhammad Mamdani, Xavier Montalban, Maria Terzaghi, Berenice Silva, Maria Laura Saladino, Philippe N Tobler, Fernando Caceres

Abstract

Background: Therapeutic inertia (TI) is a common phenomenon among physicians who care for patients with chronic conditions. We evaluated the efficacy of the traffic light system (TLS) educational intervention to reduce TI among neurologists with MS expertise. Methods: In this randomised, controlled trial, 90 neurologists who provide care to MS patients were randomly assigned to the TLS intervention (n = 45) or to the control group (n = 45). The educational intervention employed the TLS, a behavioral strategy that facilitates therapeutic choices by facilitating reflective decisions. The TLS consisted in a short, structured, single session intervention of 5-7 min duration. Participants made therapeutic choices of 10 simulated case-scenarios. The primary outcome was a reduction in TI based on a published TI score (case-scenarios in which a participant showed TI divided by the total number of scenarios where TI was possible ranging from 0 to 8). Results: All participants completed the study and were included in the primary analysis. TI was lower in the TLS group (1.47, 95% CI 1.32-1.61) compared to controls (1.93; 95% CI 1.79-2.08). The TLS group had a lower prevalence of TI compared to controls (0.67, 95% CI 0.62-0.71 vs. 0.82, 95% CI 0.78-0.86; p = 0.001). The multivariate analysis, adjusted for age, specialty, years of practice, and risk preference showed a 70% reduction in TI for the TLS intervention compared to controls (OR 0.30; 95% CI 0.10-0.89). Conclusions: In this randomized trial, the TLS strategy decreases the incidence of TI in MS care irrespective of age, expertise, years for training, and risk preference of participants, which would lead to better patient outcomes.

Keywords: decision making; disease-modifying therapy; educational intervention; multiple sclerosis; randomized clinical trial.

Figures

Figure 1
Figure 1
Consort flow diagram. Of 117 eligible participants, 90 participants were randomized to the educational intervention (n = 45) and control (n = 45). All participants completed the intervention and contributed a complete set of data to the analysis.
Figure 2
Figure 2
Experiments to assess ambiguity in the financial and health domains. Participants were told to imagine two different types or urns. For urn type A, they knew that 50% of the balls were red and the other 50% were blue. For urn type B, they did not know the exact proportion of blue to red balls, with the grey bar representing the unknown proportion of balls. For the financial domain (Panel A), participants knew that if they drew a blue ball, they would win the full amount of $400. If they drew a red ball, they would win $ 0. For the health domain (Panel B), participants decided between two treatments for a patient. With “Treatment A,” the patient had a 50% probability of survival. With “Treatment B,” the exact probability of survival was unknown, with the grey bar representing the unknown probability. In our tasks, participants were asked to choose between one option (presented as two-colored bar) with known 50/50 probability of winning 400 or 0 American dollars (urn A) versus an option with unknown probability of the same outcomes (urn B). Participants who chose the 50/50 options were classified as averse to ambiguity; the remaining participants were classified as tolerant to ambiguity. A similar approach was used to determine aversion to ambiguity in the health domain (Panel B).
Figure 3
Figure 3
The TLS intervention. Panel A illustrates background information on the TLS and application to therapeutic decisions. Panel B illustrates how the TLS facilitates the decision-making process using traffic light terminology, which creates a link between a color, representing a risk level, and an action: red light (“high risk”/“stop and think”), yellow light (“intermediate risk”/“reassess soon”), and green light (“low risk”/“continue the same strategy”). Panel C provides a case scenario as an example of those given the participants.
Figure 4
Figure 4
TLS intervention decreased therapeutic inertia (TI). (A) Comparison of adjusted TI scores in the intervention and control groups. This graph was derived from the multivariate linear regression analysis adjusted for age, years of practice, participants risk preference, and specialty (general neurologist v. MS expert). TI scores were significantly higher in the control group compared to the intervention group (*P value <0.001). (B) Comparison of adjusted prevalence of TI between the intervention and control groups. This graph was derived from the multivariate logistic regression analysis adjusted for age, years of practice, participants risk preference, and specialty (general neurologist v. MS expert). The prevalence of TI was significantly higher in the control group compared with the intervention group (*P value <0.001).
Figure 5
Figure 5
Adjusted probability of therapeutic inertia (TI). (A) Adjusted probability of TI as a function of TI scores. (B) Adjusted TI score categories stratified by intervention assignment group. The x-axis represents categories of the TI to evaluate whether the intervention had a different effect among participants with low, medium, and high TI scores. The y-axis represents the TI scores to be able to show the lack of overlap of 95% CI between TLS and controls for each TI category (P value TLS v. controls = 0.02). Data derived from multivariate linear regression with TI score as the dependent variable. “I” represent 95% CI error bars.

References

    1. O’Connor PJ, Sperl-Hillen JAM, Johnson PE, Rush WA, Biltz G. Clinical inertia and outpatient medical errors. In: Henriksen K, Battles JB, Marks ES, Lewin DI, eds. Advances in Patient Safety: From Research to Implementation (Volume 2: Concepts and Methodology). Rockville (MD): Agency for Healthcare Research and Quality; 2005.
    1. Ziemssen T, Derfuss T, de Stefano N, et al. Optimizing treatment success in multiple sclerosis. J Neurol. 2016;263(6):1053–65. doi:10.1007/s00415-015-7986-y
    1. Saposnik G, Sempere AP, Prefasi D, et al. Decision-making in multiple sclerosis: the role of aversion to ambiguity for therapeutic inertia among neurologists (DIScUTIR MS). Front Neurol. 2017;8:65. doi:10.3389/fneur.2017.00065
    1. Mohan AV, Phillips LS. Clinical inertia and uncertainty in medicine. JAMA. 2011;306(4):383.
    1. Phillips LS, Branch WT, Cook CB, et al. Clinical inertia. Ann Intern Med. 2001;135(9):825–34.
    1. Okonofua EC, Simpson KN, Jesri A, Rehman SU, Durkalski VL, Egan BM. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension. 2006;47(3):345–51. doi:10.1161/01.HYP.0000200702
    1. Gongora-Ortega J, Segovia-Bernal Y, Valdivia-Martinez Jde J, Galaviz-DeAnda JM, Prado-Aguilar CA. Educational interventions to improve the effectiveness in clinical competence of general practitioners: problem-based versus critical reading-based learning. BMC Med Educ. 2012;12:53. doi:10.1186/1472-6920-12-53
    1. Kennedy T, Regehr G, Rosenfield J, Roberts SW, Lingard L. Exploring the gap between knowledge and behavior: a qualitative study of clinician action following an educational intervention. Acad Med. 2004;79(5):386–93.
    1. Djulbegovic B, Beckstead JW, Elqayam S, et al. Evaluation of physicians’ cognitive styles. Med Decis Making. 2014;34(5):627–37. doi:10.1177/0272989X14525855
    1. Kostopoulou O, Sirota M, Round T, Samaranayaka S, Delaney BC. The role of physicians’ first impressions in the diagnosis of possible cancers without alarm symptoms. Med Decis Making. 2017;37(1):9–16. doi:10.1177/0272989X16644563
    1. Dijkstra IS, Pols J, Remmelts P, Brand PL. Preparedness for practice: a systematic cross-specialty evaluation of the alignment between postgraduate medical education and independent practice. Med Teach. 2015;37(2):153–61. doi:10.3109/0142159X.2014.929646
    1. Monrouxe LV, Grundy L, Mann M, et al. How prepared are UK medical graduates for practice? A rapid review of the literature 2009–2014. BMJ Open. 2017;7(1):e013656. doi:10.1136/bmjopen-2016-013656
    1. Kostopoulou O, Russo JE, Keenan G, Delaney BC, Douiri A. Information distortion in physicians’ diagnostic judgments. Med Decis Making. 2012;32:831–9. doi:10.1177/0272989X12447241
    1. Sonnenberg L, Gelsomin E, Levy DE, Riis J, Barraclough S, Thorndike AN. A traffic light food labeling intervention increases consumer awareness of health and healthy choices at the point-of-purchase. Prev Med. 2013;57(4):253–7. doi:10.1016/j.ypmed.2013.07.001
    1. Murphy MS, Baker M. When used appropriately, NICE’s traffic light system for febrile children helps clinicians make safe and appropriate decisions. BMJ. 2014;348:g2518. doi:10.1136/bmj.g2518
    1. Enax L, Krajbich I, Weber B. Salient nutrition labels increase the integration of health attributes in food decision-making. Judgment Decis Making. 2016;11(5):460–71.
    1. Enax L, Krapp V, Piehl A, Weber B. Effects of social sustainability signaling on neural valuation signals and taste-experience of food products. Front Behav Neurosci. 2015;9:247. doi:10.3389/fnbeh.2015.00247
    1. Phillips AC, Lewis LK, McEvoy MP, et al. Development and validation of the guideline for reporting evidence-based practice educational interventions and teaching (GREET). BMC Med Educ. 2016;16(1):237. doi:10.1186/s12909-016-0759-1
    1. Saposnik G, Maurino J, Sempere AP, et al. Overcoming therapeutic inertia in multiple sclerosis care: a pilot randomized trial applying the traffic light system in medical education. Front Neurol. 2017;8:430. doi:10.3389/fneur.2017.00430
    1. Saposnik G, Tobler PN, Caceres F, et al. Usability of an educational intervention to overcome therapeutic inertia in multiple sclerosis care. Front Neurol. 2018;9:522. doi:10.3389/fneur.2018.00522
    1. Levy I, Snell J, Nelson AJ, Rustichini A, Glimcher PW. Neural representation of subjective value under risk and ambiguity. J Neurophysiol. 2010;103(2):1036–47. doi:10.1152/jn.00853.2009
    1. Anderson LR, Mellor JM. Predicting health behaviors with an experimental measure of risk preference. J Health Econ. 2008;27(5):1260–74. doi:10.1016/j.jhealeco.2008.05.011
    1. Peabody JW, Luck J, Glassman P, Dresselhaus TR, Lee M. Comparison of vignettes, standardized patients, and chart abstraction: a prospective validation study of 3 methods for measuring quality. JAMA. 2000;283(13):1715–22.
    1. Cristiano E, Alonso R, Pinheiro AA, et al. Argentinean recommendations on the identification of treatment failure in relapsing remitting multiple sclerosis patients. J Neurol Sci. 2018;385:217–24. doi:10.1016/j.jns.2018.01.004
    1. Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018;24(2):96–120. doi:10.1177/1352458517751049
    1. Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the guideline development, dissemination, and implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90(17):777–88. doi:10.1212/WNL.0000000000005347
    1. Prosperini L, Mancinelli CR, De Giglio L, De Angelis F, Barletta V, Pozzilli C. Interferon beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosis. Mult Scler. 2014;20(5):566–76. doi:10.1177/1352458513502399
    1. Bermel RA, You X, Foulds P, et al. Predictors of long-term outcome in multiple sclerosis patients treated with interferon β. Ann Neurol. 2013;73(1):95–103. doi:10.1002/ana.23758
    1. Sormani MP, Rio J, Tintore M, et al. Scoring treatment response in patients with relapsing multiple sclerosis. Mult Scler. 2013;19(5):605–12. doi:10.1177/1352458512460605
    1. Sormani MP, Gasperini C, Romeo M, et al. Assessing response to interferon-β in a multicenter dataset of patients with MS. Neurology. 2016;87(2):134–40. doi:10.1212/WNL.0000000000002830
    1. Sormani MP, De Stefano N. Defining and scoring response to IFN-β in multiple sclerosis. Nat Rev Neurol. 2013;9(9):504–12. doi:10.1038/nrneurol.2013.146
    1. Tramacere I, Del Giovane C, Salanti G, D’Amico R, Filippini G. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev. 2015;(9):CD011381. doi:10.1002/14651858.CD011381.pub2
    1. Saposnik G, Montalban X. Therapeutic inertia in the new landscape of multiple sclerosis care. Front Neurol. 2018;9:174. doi:10.3389/fneur.2018.00174
    1. Saposnik G, Montalban X, Selchen D, et al. Therapeutic inertia in multiple sclerosis care: a study of Canadian neurologists. Front Neurol. 2018;9:781. doi:10.3389/fneur.2018.00781
    1. Albarqouni L, Hoffmann T, Glasziou P. Evidence-based practice educational intervention studies: a systematic review of what is taught and how it is measured. BMC Med Educ. 2018;18(1):177. doi:10.1186/s12909-018-1284-1
    1. Stangel M, Penner IK, Kallmann BA, Lukas C, Kieseier BC, Gold R. Multiple Sclerosis Decision Model (MSDM): Entwicklung eines Mehrfaktorenmodells zur Beurteilung des Therapie- und Krankheitsverlaufs bei schubförmiger Multipler Sklerose. Akt Neurol. 2013;40(9):486–93. doi:10.1055/s-0033-1349643

Source: PubMed

3
Abonneren